Filter
Reset all

Subjects

Content Types

Countries

AID systems

API

Certificates

Data access

Data access restrictions

Database access

Database access restrictions

Database licenses

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

Metadata standards

PID systems

Provider types

Quality management

Repository languages

Software

Syndications

Repository types

Versioning

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
Found 66 result(s)
Country
From April 2020 to March 2023, the Covid-19 Immunity Task Force (CITF) supported 120 studies to generate knowledge about immunity to SARS-CoV-2. The subjects addressed by these studies include the extent of SARS-CoV-2 infection in Canada, the nature of immunity, vaccine effectiveness and safety, and the need for booster shots among different communities and priority populations in Canada. The CITF Databank was developed to further enhance the impact of CITF funded studies by allowing additional research using the data collected from CITF-supported studies. The CITF Databank centralizes and harmonizes individual-level data from CITF-funded studies that have met all ethical requirements to deposit data in the CITF Databank and have completed a data sharing agreement. The CITF Databank is an internationally unique resource for sharing epidemiological and laboratory data from studies about SARS-CoV-2 immunity in different populations. The types of research that are possible with data from the CITF Databank include observational epidemiological studies, mathematical modelling research, and comparative evaluation of surveillance and laboratory methods.
Country
The Biobanque québécoise de la COVID-19 (BQC19) is a pan-provincial initiative that collects, stores and shares data and blood samples from COVID-19 patients, both severe and non-severe cases and control cases, in an effort to respond effectively to the public health challenges posed by the pandemic. BQC19 believes that better understanding the disease will help society in returning to social activities and in preparing for future pandemics. It sees access to high-quality samples and data as essential in fulfilling research and works to bring about national and international research collaborations.
Country
CanPath is Canada’s largest population health cohort and a national platform for population-level health research.It is a unique Canadian platform allowing scientists to explore the complex factors that contribute to disease. It is a deeply characterized cohort of individuals who have provided broad consent and now include two per cent of all Canadians between 30 and 74 years of age. CanPath can save researchers time — sometimes up to a decade — associated with arranging and measuring their own population samples. Researchers around the world can readily integrate CanPath data into their own studies. The standardization and harmonization of data across CanPath’s regional cohorts has been facilitated by Maelstrom Research.
The Infectious Diseases Data Observatory (IDDO) assembles clinical, laboratory and epidemiological data on a collaborative platform to be shared with the research and humanitarian communities. The data are analysed to generate reliable evidence and innovative resources that enable research-driven responses to the major challenges of emerging and neglected infections. Access is available to individual patient data held for malaria and Ebola virus disease. Resources for visceral leishmaniasis, schistosomiasis and soil transmitted helminths, Chagas disease and COVID-19 are under development. IDDO contains the following repositories : COVID-19 Data Platform, Chagas Data Platform, Schistosomiasis & Soil Transmitted Helminths Data Platform, Visceral Leishmaniasis Data Platform, Ebola Data Platform, WorldWide Antimalarial Resistance Network (WWARN)
Project Data Sphere, LLC, operates a free digital library-laboratory where the research community can broadly share, integrate and analyze historical, de-identified, patient-level data from academic and industry cancer Phase II-III clinical trials. These patient-level datasets are available through the Project Data Sphere platform to researchers affiliated with life science companies, hospitals and institutions, as well as independent researchers, at no cost and without requiring a research proposal.
Patients-derived tumor xenograft (PDX) mouse models are an important oncology research platform to study tumor evolution, drug response and personalised medicine approaches. We have expanded to organoids and cell lines and are now called CancerModels.Org
BEI Resources was established by the National Institute of Allergy and Infectious Diseases (NIAID) to provide reagents, tools and information for studying Category A, B, and C priority pathogens, emerging infectious disease agents, non-pathogenic microbes and other microbiological materials of relevance to the research community. BEI Resources acquires authenticates, and produces reagents that scientists need to carry out basic research and develop improved diagnostic tests, vaccines, and therapies. By centralizing these functions within BEI Resources, access to and use of these materials in the scientific community is monitored and quality control of the reagents is assured
Vivli is a non-profit organization working to advance human health through the insights and discoveries gained by sharing and analyzing data. It is home to an independent global data-sharing and analytics platform which serves all elements of the international research community. The platform includes a data repository, in-depth search engine and cloud-based analytics, and harmonizes governance, policy and processes to make sharing data easier. Vivli acts as a neutral broker between data contributor and data user and the wider data sharing community.
It is a platform for supporting Open Data initiative of Government of Odisha, intends to publish datasets collected by them for public use. It also supports widely used file formats that are suitable for machine processing, thus gives avenues for many more innovative uses of Government Data in different perspective. This portal has been created under Software as A Service (SaaS) model of Open Government Data (OGD) Platform India of NIC. The data available in the portal are owned by various Departments/Organization of Government of Odisha. It follows principles on which data sharing and accessibility need to be based include: Openness, Flexibility, Transparency, Quality, Security and Machine-readable.
Country
It is a platform (designed and developed by the National Informatics Centre (NIC), Government of India) for supporting Open Data initiative of Surat Municipal Corporation, intended to publish government datasets for public use. The portal has been created under Software as A Service (SaaS) model of Open Government Data (OGD) Platform, thus gives avenues for resuing datasets of the City in different perspective. This Portal has numerious modules; (a) Data Management System (DMS) for contributing data catalogs by various departments for making those available on the front end website after a due approval process through a defined workflow; (b) Content Management System (CMS) for managing and updating various functionalities and content types of Open Government Data Portal of Surat City; (c) Visitor Relationship Management (VRM) for collating and disseminating viewer feedback on various data catalogs; and (d) Communities module for community users to interact and share their zeal and views with others, who share common interests as that of theirs.
Country
The German National Cohort (NAKO) has been inviting men and women aged between 20 and 69 to 18 study centers throughout Germany since 2014. The participants are medically examined and questioned about their living conditions. The GNC’s aim is to investigate the causes of chronic diseases, such as cancer, diabetes, cardiovascular diseases, rheumatism, infectious diseases, and dementia in order to improve prevention, early diagnoses and treatment of these very widely spread diseases.
Country
With its “Blood Donor BIOBANK”, the Bavarian Red Cross (BRK) Blood Donor Service offers a unique and innovative resource for biomarker research: the world’s first blood donor based biobank. Biobanks as collections of biological material together with associated medical data open new possibilities for the development of new targeted diagnostics and therapies. The BRK Blood Donor Service maintains a unique collection of over 3 million blood samples, making it one of the largest sample collections worldwide. Every working day 2,000 new samples are added to the collection.
The FREEBIRD website aims to facilitate data sharing in the area of injury and emergency research in a timely and responsible manner. It has been launched by providing open access to anonymised data on over 30,000 injured patients (the CRASH-1 and CRASH-2 trials).
Country
The JenAge Ageing Factor Database AgeFactDB is aimed at the collection and integration of ageing phenotype and lifespan data. Ageing factors are genes, chemical compounds or other factors such as dietary restriction, for example. In a first step ageing-related data are primarily taken from existing databases. In addition, new ageing-related information is included both by manual and automatic information extraction from the scientific literature. Based on a homology analysis, AgeFactDB also includes genes that are homologous to known ageing-related genes. These homologs are considered as candidate or putative ageing-related genes.
The CPTAC Data Portal is the centralized repository for the dissemination of proteomic data collected by the Proteome Characterization Centers (PCCs) for the CPTAC program. The portal also hosts analyses of the mass spectrometry data (mapping of spectra to peptide sequences and protein identification) from the PCCs and from a CPTAC-sponsored common data analysis pipeline (CDAP).
Country
SAGE is a data and research platform that enables the secondary use of data related to child and youth development, health and well-being. It currently contains research data, and at a later stage we aim to also house administrative and community service delivery data. Technical infrastructure and governance processes are in place to ensure ethical use and the privacy of participants. This dataverse provides metadata for the various data holdings available in SAGE (Secondary Analysis to Generate Evidence), a research data repository based in Edmonton Alberta and an intiative of PolicyWise for Children & Families. In general, SAGE contains data holdings too sensitive for open access. Each study lists a security level which indicates the procedure required to access the data.
The Cancer Immunome Database (TCIA) provides results of comprehensive immunogenomic analyses of next generation sequencing data (NGS) data for 20 solid cancers from The Cancer Genome Atlas (TCGA) and other datasource. The Cancer Immunome Atlas (TCIA) was developed and is maintained at the Division of Bioinformatics (ICBI). The database can be queried for the gene expression of specific immune-related gene sets, cellular composition of immune infiltrates (characterized using gene set enrichment analyses and deconvolution), neoantigens and cancer-germline antigens, HLA types, and tumor heterogeneity (estimated from cancer cell fractions). Moreover it provides survival analyses for different types immunological parameters. TCIA will be constantly updated with new data and results.
Country
Androgen Receptor Gene Mutations Database is for all who are interested in mutations of the Androgen Receptor Gene. In light of the difficulty in getting new AR mutations published the curator will now accept new mutations that have not been published, provided that it is from a reputable research or clinical laboratory. The curator also strongly suggests that where possible, particularly in the case of new unique mutations that an attempt be made to at least confirm the pathogenicity of the putatative mutation, by showing that the mutation when transfected into a suitable expression system produces a mutant androgen receptor protein.